Membership Directory
Arteriocyte Inc.
Category: Drug Development
Phone: 216-658-3970
Fax: 216-229-7323
Website: http://www.arteriocyte.com
Arteriocyte is a clinical stage research and development biotechnology company that is developing proprietary, non-embryonic stem cell-based therapies targeted for the treatment of ischemia in patients suffering from coronary artery disease, peripheral vascular disease, stroke, and renal ischemia. The Company was founded in January of 2004 based upon more than four years of NIH-sponsored research utilizing stem cells to stimulate angiogenesis (new vessel growth). Arteriocyte’s ultimate goal is to develop umbilical cord blood - a rich source of stem cells - as the basis for the company’s future cellular medicines. The company is currently conducting a Phase I clinical trial in the US (under an FDA approved IND) for an adult, bone-marrow-derived stem cell therapy designed to generate new blood vessels in ischemic tissues in patients suffering Chronic Ischemia. The clinical study is underway at University Hospitals of Cleveland.
Back to list



PHONE: 617.674.5100
EMAIL: